Click to edit Footer title style Randomized Trial of Bead Block TM vs Embosphere TM for UAE for Fibroids Robert L Worthington-Kirsch, MD, FSIR, FCIRSE,

Slides:

Advertisements

Similar presentations

Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.

Advertisements

The Diabetic Retinopathy Clinical Research Network

Synopsis of FDA Colorectal Cancer Endpoints Workshop Michael J. O’Connell, MD Director, Allegheny Cancer Center Associate Chairman, NSABP Pittsburgh, PA.

Intracoronary Autologous Bone-Marrow Cell Transfer after Myocardial Infarction: A Double-Blind, Randomized, and Placebo-Controlled Clinical Trial Presented.

Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure Presented at American College of Cardiology Scientific Sessions.

Copyleft Clinical Trial Results. You Must Redistribute Slides SEISMIC Trial The Safetyand Effects of Implanted (Autologous) Skeletal Myoblasts (MyoCell)

ARTIFICIAL DISC VERSUS FUSION A prospective randomised study with 2-year follow-up on 99 patients.

ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.

Outcome after interventional or conservative management of unruptured brain arteriovenous malformations: a prospective, population-based cohort study Lancet.

Long-term predictive value of assessment of coronary atherosclerosis by contrast- enhanced coronary computed tomography angiography: meta- analysis and.

Uterine Fibroid Embolization

Peginterferon  2a/Ribavirin FDA Antiviral Drugs Advisory Committee Brian Murphy, MD, MPH, MS InterMune Submitted November 12, 2002 for Presentation November.

Copyright restrictions may apply A Randomized Trial of Nebulized 3% Hypertonic Saline With Epinephrine in the Treatment of Acute Bronchiolitis in the Emergency.

Enhanced MR guided Focused Ultrasound Surgery (MRgFUS) Guidelines Demonstrates Improved Efficacy and Durability for the Treatment of Uterine Myoma Phyllis.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

1 FDA Review of NDA Valganciclovir for the Treatment of CMV Retinitis in AIDS Joseph Toerner, MD Medical Officer DAVDP.

Quality of life improves after patients switch to biphasic insulin aspart 30/70 (BIAsp 30): IMPROVE™ Study data from 39,015 patients M. Benroumpi 1, T.

Design: A randomized, prospective, double-blind cohort followed for 16 weeks RenehaVis Original Study 50 DMW 50 HMW 50 LMW 50 Placebo.

Target Study Cardiac resynchronization therapy (CRT) is an established treatment for advanced heart failure symptoms, impaired LV systolic function, and.

Jay H. Traverse, MD Principal Investigator, TIME Study Minneapolis Heart Institute at Abbott Northwestern Hospital University of Minnesota Medical School.

Placebo-Controls in Short-Term Clinical Trials of Hypertension Sana Al-Khatib, MD, MHS Assistant Professor of Medicine Division of Cardiology Duke University.

Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.

1 SNDA Gemzar plus Carboplatin Treatment of Late Relapsing Ovarian Cancer.

Barb Supanich, RSM, MD, FAAHPM Holy Cross IP Palliative Care Team November 11, 2010.

SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.

Critical Appraisal Did the study address a clearly focused question? Did the study address a clearly focused question? Was the assignment of patients.

RevMan for Registrars Paul Glue, Psychological Medicine What is EBM? What is EBM? Different approaches/tools Different approaches/tools Systematic reviews.

The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.

Brigham and Women’s Hospital, Department of Radiology

CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.

DHHS / FDA / CDRH 1 FDA Summary CardioSEAL® STARFlex™ Septal Occlusion System with Qwik Load NMT Medical P000049/S3.

Occluded Artery Trial (OAT) Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Judith S. Hochman OAT Trial.

Continuous Loop Double Endobutton Reconstruction for AC Joint Dislocation Steven Struhl, MD 1, Theodore Wolfson, MD 1 1 Department of Orthopaedic Surgery,

The Diabetic Retinopathy Clinical Research Network Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control (Protocol M) 11.

1 Infarction End Point in Bland Embolisation and Drug-Eluting Beads UFE treatment: long term follow up of Bead Block registry Dr Thomas J Kroencke Department.

How To Design a Clinical Trial

Critical Appraisal (CA) I Prepared by Dr. Hoda Abd El Azim.

EVALUATING u After retrieving the literature, you have to evaluate or critically appraise the evidence for its validity and applicability to your patient.

H. EL MORABIT, N. EL YOUSFI, S. BOUKLATA. Medical emergency imagery IBN SINA Hospital. INTERVENTIONAL : INTV1 INTV1.

CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.

: Intermittent Neurogenic Claudication Aperius ® Percutaneous Interspinous Spacer F. Collignon, P. Fransen, D Morelli, N. Craig, J. Van Meirhaeghe For.

A-4 Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Pierre Jais Atrial Fibrillation Ablation vs. Antiarrhythmic Drugs Trial.

Late Open Artery Hypothesis Jason S. Finkelstein, M.D. Tulane University Medical Center 2/24/03.

Efficacy of Topical Azithromycin & Cyclosporine A(CsA) vs CsA Alone in the Treatment of Dry Eyes Associated with Blepharitis Kenneth A. Beckman, M.D.,

Acute Bacterial Otitis Media Summary and Charge to the Committee Renata Albrecht, M.D. Division of Special Pathogen and Immunologic Drug Products ODEIV,

Methodological Issues in Implantable Medical Device(IMDs) Studies Abdallah ABOUIHIA Senior Statistician, Medtronic.

Why Treat Patent Forman Ovale Clifford J Kavinsky, MD, PHD Professor of Medicine and pediatrics Associate Director, Center for Congenital and Structural.

Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.

Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.

Purpose: The purpose of this study is to investigate the treatment results, and procedure-related complications of stent-angioplasty for symptomatic intracranial.

Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented at.

Uterine Artery Embolization: Technique and Outcomes

UOG Journal Club: February 2017

Total Occlusion Study of Canada (TOSCA-2) Trial

The NHLBI TIME Trial: Role of Microvascular Obstruction in 2-Year Clinical and MRI Follow-up Jay H. Traverse, MD Principal Investigator, TIME Study Minneapolis.

How To Design a Clinical Trial

Uterine artery embolization vs hysterectomy in the treatment of symptomatic uterine fibroids: 5-year outcome from the randomized EMMY trial Sanne M.

The American College of Cardiology Presented by Dr. Adnan Kastrati

Prospective Evaluation of the Embolic Agent Bead Block in the Treatment of Uterine Leiomyomas with Uterine Artery Embolization: A Phase II Study Howard.

Latest Data from Balloon Expendable Trials

Martha Carvour, MD, PhD March 2, 2017

Erica Takai, PhD for Andrew Farb, M.D.

Setareh Omran, MD Vascular Neurology Fellow

Nishith Patel Waikato Cardiothoracic Unit

What Is New in HCM?.

The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.

Extended Window Thrombectomy

The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.

Main inclusion criteria)

The Ontario Uterine Fibroid Embolization Trial. Part 2

Presentation transcript:

Click to edit Footer title style Randomized Trial of Bead Block TM vs Embosphere TM for UAE for Fibroids Robert L Worthington-Kirsch, MD, FSIR, FCIRSE, RVT, RPVI

Click to edit Footer title style Disclosures This study is supported by an unrestricted grant from Biocompatibles and Terumo Dr Worthington-Kirsch is an active consultant to Biocompatibles, Terumo, Biosphere Medical, and Vascular Solutions

Click to edit Footer title style Background UAE has been established as mainstream therapy for fibroid disease Embolic choice evolving Calibrated hydrogel spheres preferred Tris-acryl/gelatin most commonly used PVA hydrogel is an emerging alternative

Click to edit Footer title style PVA Hydrogel Spheres Very similar to soft contact lenses PVA has been used as implanted biomaterial since the 1940s Very different properties than non-hydrogel PVA preparations

Click to edit Footer title style Study Rationale Clinical experience suggests that BB as effective as ES for UAE Requires proper technique Randomized trial needed to confirm or disprove anecdotal experience

Click to edit Footer title style Study Design Non-inferiority 22 patients per arm gives desired power PRCT (Level I data) Patients not informed about embolic used MRI grader blinded for embolic used Reviewed/approved by FDA

Click to edit Footer title style Admission Criteria Similar to other UAE studies Women ages Symptomatic fibroids without other uterine disease Uterus >250cc, <24 weeks

Click to edit Footer title style Study Design MRIs on designated magnet Pre-UAE, 3-7 days post-UAE, 3 months, 6 months Best protocol for each embolic BB – start with ES – start with , unless Ovarian A seen Terumo Progreat microcatheter Consistent defined embolization endpoints

Click to edit Footer title style Embolization Endpoints New filling of Ovarian A or cross-uterine collaterals Retrograde flow around catheter tip “Plumping” of artery with injection No further filling of ascending branch

Click to edit Footer title style Outcome Measures MRI fibroid perfusion “immediate”, 3 months, 6 months Uterine/dominant fibroid size UFS-QOL 3 months, 6 months, 1 year

Click to edit Footer title style Study to Date 2 cohorts Site 1 – 22 patients Complete follow-up data set 1 technical failure (anatomic basis) Site 2 – patients 1 withdrawal from initial 22 Follow-up complete except for 12 month QOLs 22 analyzable patients in each arm

Click to edit Footer title style Study to Date No serious complications All UAEs clinically successful per patients Including technical failure 3 “failures” to discuss in more detail

Click to edit Footer title style Study to Date – Follow Up 1 Week post-UAE (MRI only) – 43/44 (97%, 1 ES) 3 Mo post-UAE MRI – 36/44 (82%, 5 ES, 3 BB) QOL – 39/44 (88%, 3 ES, 2 BB) 6 Mo post-UAE MRI – 37/44 (84%, 4 ES, 3 BB) QOL – 43/44 (97%, 1 BB) 12 Mo post UAE (QOL only) – 21/21

Click to edit Footer title style MRI Grading Pre-UAE perfusion scored at 10 Global fibroid burden, not just dominant fibroid Follow-up perfusion scored – Complete infarction all visible fibroids “Success” (10% or less residual perfusion) 3-4 – “Partial Success” (11-30% residual perfusion) 5 or higher - “Failure” (>30% residual perfusion)

Click to edit Footer title style Fibroid Perfusion

Click to edit Footer title style Volume

Click to edit Footer title style UFS-QOL Grading Symptom Score, QOL Score. QOL Subscales Change of 10 points or greater significant

Click to edit Footer title style UFS-QOL

Click to edit Footer title style UFS-QOL

Click to edit Footer title style QOL Subscales Bead Block Embosphere

Click to edit Footer title style QOL Subscales

Click to edit Footer title style QOL Subscales

Click to edit Footer title style QOL Subscales

Click to edit Footer title style QOL Subscales

Click to edit Footer title style Treatment Failures? Patient # Embosphere Complete infarction at 1 week and 3 months Significant reperfusion (4) at 6 months SS94>44>0 QOL 86>89>96 Will symptoms recur?

Click to edit Footer title style Treatment Failures? Patient # Bead Block Almost complete infarction (2) on all f/u MRIs SS41>69>66 (worsening) QOL 66>50>52 (borderline improvement)

Click to edit Footer title style Treatment Failures? Patient # Embosphere Perfusion score 1 week, then 2 SS47>25>31 QOL 53>56>51

Click to edit Footer title style Treatment Failures? General consensus in literature is that UAE failure rate is ~10%. 3 Failures out of 44 patients is not unexpected.

Click to edit Footer title style Data Supports Noninferiority UFS - QOL Symptom SeverityStudent TSig (  =95%) Baseline.3075Y 3 Month.2406Y 6 Month.1289Y Overall QOL Baseline to Baseline.8235Y 3 Mo BB vs ES.0005N 3 Mo change.1950Y 6 Mo BB vs ES.2002Y 6 Mo change37252Y

Click to edit Footer title style Data Supports Noninferiority Perfusion

Click to edit Footer title style Data Supports Noninferiority Volume Reduction

Click to edit Footer title style Spies – “How to Evaluate New Embolics” Well–defined inclusion/exclusion criteria Adequate sample size/power analysis Randomization by independent third party Double-blinding Identical care and follow-up

Click to edit Footer title style Spies – “How to Evaluate New Embolics” Well–defined inclusion/exclusion criteria Adequate sample size/power analysis Randomization by independent third party Double-blinding Identical care and follow-up

Click to edit Footer title style Spies – “How to Evaluate New Embolics” Well–defined inclusion/exclusion criteria Adequate sample size/power analysis Randomization by independent third party Double-blinding Identical care and follow-up

Click to edit Footer title style Spies – “How to Evaluate New Embolics” Well–defined inclusion/exclusion criteria Adequate sample size/power analysis Randomization by independent third party Double-blinding Identical care and follow-up

Click to edit Footer title style Spies – “How to Evaluate New Embolics” Well–defined inclusion/exclusion criteria Adequate sample size/power analysis Randomization by independent third party Double-blinding Identical care and follow-up

Click to edit Footer title style Spies – “How to Evaluate New Embolics” Well–defined inclusion/exclusion criteria Adequate sample size/power analysis Randomization by independent third party Double-blinding Identical care and follow-up

Click to edit Footer title style Spies – “How to Evaluate New Embolics” Intention to treat analysis Blinded imaging assessment Clear endpoint assessment UFS-QOL, Enhanced MRI Reporting

Click to edit Footer title style Spies – “How to Evaluate New Embolics” Intention to treat analysis Blinded imaging assessment Clear endpoint assessment UFS-QOL, Enhanced MRI Reporting

Click to edit Footer title style Spies – “How to Evaluate New Embolics” Intention to treat analysis Blinded imaging assessment Clear endpoint assessment UFS-QOL, Enhanced MRI Reporting

Click to edit Footer title style Spies – “How to Evaluate New Embolics” Intention to treat analysis Blinded imaging assessment Clear endpoint assessment UFS-QOL, Enhanced MRI Reporting

Click to edit Footer title style Spies – “How to Evaluate New Embolics” Intention to treat analysis Blinded imaging assessment Clear endpoint assessment UFS-QOL, Enhanced MRI Reporting

Click to edit Footer title style Spies – “How to Evaluate New Embolics” Intention to treat analysis Blinded imaging assessment Clear endpoint assessment UFS-QOL, Enhanced MRI Reporting

Click to edit Footer title style Questions?